NASDAQ:SRNE
Delisted
Sorrento Therapeutics Stock News
$0.307
+0 (+0%)
At Close: Feb 23, 2023
Sorrento CEO Henry Ji on How the Company Got Its Start
10:07am, Thursday, 19'th Nov 2020
The company's focus on antibodies helped it pivot into COVID-19.
The Breakthrough for Sorrento Could Be Just Around the Corner
10:52am, Wednesday, 18'th Nov 2020
If you'd like to wager on a company with a packed clinical pipeline featuring potential Covid-19 treatments, SRNE stock is a great choice. The post The Breakthrough for Sorrento Could Be Just Around t
A Vulnerable Pipeline Continues to Weigh Down Sorrento Stock
07:52am, Wednesday, 18'th Nov 2020
Sorrento stock continues to be weighed down by the companys inefficacious product pipeline making it an incredibly risky investment. The post A Vulnerable Pipeline Continues to Weigh Down Sorrento Sto
Unless Sorrento Makes Solid Progress Soon, It Will Likely Go Below $5
09:06am, Tuesday, 17'th Nov 2020
SRNE stock is a speculative play in the race to develop a Covid-19 therapy The post Unless Sorrento Makes Solid Progress Soon, It Will Likely Go Below $5 appeared first on InvestorPlace. More From Inv
Novavax and Sorrento Therapeutics: Are These Beaten-Down Coronavirus Stocks a Bargain?
10:00am, Monday, 16'th Nov 2020
Novavax and Sorrento Therapeutics have been on a sharp downward trajectory.
Is It Time to Buy Sorrento Stock After Its Month-Long Swoon?
02:52pm, Friday, 13'th Nov 2020
Sorrento stock has lost 50% over the past month. Investors have grown impatient with the company's Covid-19 efforts.
Why Sorrento Therapeutics Stock Is Jumping Today
12:18pm, Wednesday, 11'th Nov 2020
The company hopes to win FDA approval to begin another early-stage COVID-19 clinical study.
I Would Not Be Surprised If SRNE Stock Trades Below $5
11:15am, Wednesday, 11'th Nov 2020
SRNE stock is a purely speculative bet. The company has a deep pipeline of Covid-19 programs.
Sorrento Announces IND Filing for COVI-DROPS, an Intranasal Formulation of a High Potency Neutralizing Antibody Against SARS-CoV-2
09:00am, Wednesday, 11'th Nov 2020
SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it is filing an investigational new drug application (IND) for intranasal (
Sorrento Stock Is Still in this Fight but Better Buckle Up
09:57am, Tuesday, 10'th Nov 2020
Biotech companies typically live and die by headlines. SRNE stock has had better days, so they need one soon for the sake of its investors.
Sorrento Keeps Falling as the Pipeline Fails to Deliver
08:05am, Tuesday, 10'th Nov 2020
SRNE stock had its chance in 2020. But with its Covid-19 efforts failing to deliver concrete results, traders are dumping their shares.
Sorrento Therapeutics Files IND for Coronavirus Treatment
06:39pm, Monday, 09'th Nov 2020
If the FDA approves the application, STI-2020 would enter human clinical trials.
Here's Why Sorrento Therapeutics Plummeted 37.8% in October
06:16pm, Monday, 09'th Nov 2020
Investors grow weary of the high-flying COVID-19 company.
Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2
09:00am, Monday, 09'th Nov 2020
SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it is filing an investigational new drug application (IND) for intravenous
Your First Instinct About Sorrento Therapeutics Is Probably Right
08:42am, Tuesday, 03'rd Nov 2020
SRNE stock is down nearly 66% since August. The company is taking many swings at finding solutions for Covid-19, but it's runway simply isn't long enough.
